Clinical Trial Update: A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases [Phase 2]

View source ↗

Summary

This clinical trial is evaluating Utidelone injection plus capecitabine in HER2-negative breast cancer patients with brain metastases in Phase II, currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Utidelone (utidelone)

Snippet

Sponsor: Biostar Pharma, Inc. | Conditions: HER2-negative Breast Cancer Patients With Brain Metastases | Phase 2 | Status: RECRUITING